查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2080351

幹細胞市場：全球市場按細胞類型、來源、技術、應用和最終用戶分類的預測——2026-2032年

Stem Cells Market by Cell Type, Cell Source, Technology, Cell Source, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，幹細胞市場規模將達到 331.8 億美元，年複合成長率為 11.26%。

主要市場統計數據
基準年 2025 157.2億美元
預計年份：2026年 174億美元
預測年份 2032 331.8億美元
複合年成長率 (%) 11.26%

幹細胞市場執行摘要

幹細胞是再生醫學、細胞療法、疾病模型、藥物研發和生物製造的核心。這領域涵蓋用於移植的造血幹細胞、間質幹細胞、胚胎幹細胞、誘導多功能細胞以及成體組織特異性幹細胞，這些幹細胞被用於免疫調節和組織修復的研究。推動商業性發展的動力源自於多面向因素，包括對永續療法的臨床需求、更完善的表徵工具、可擴展的生產方式，以及來自美國FDA、EMA、PMDA、加拿大衛生部和日本衛生署勞動省等監管機構更為明確的監管要求。

幹細胞領域的變革性變化

幹細胞領域正從探索性研究轉向基於平台的臨床應用。十年前，許多項目受限於細胞表徵不一致、小批量生產和臨床終點不確定等問題。如今，單細胞分析、療效檢測、密封系統處理、冷凍保存技術、數位化批次記錄以及標準化供體篩檢方法等方面的進步，使研發人員能夠在臨床試驗的各個階段降低變異性並提高可比性。

人工智慧對幹細胞領域的累積影響

人工智慧正整體成為幹細胞研究和商業化領域的重要驅動力。在藥物發現階段，機器學習可輔助解讀單細胞轉錄組學資料、進行細胞狀態分類、最佳化分化方案、進行基於影像的表現型分析以及標靶辨識。在生產階段，電腦視覺和預測分析能夠監測細胞形態、培養條件、污染風險、培養基性能以及批次間一致性，從而減少對主觀人工評估的依賴。

幹細胞領域的關鍵區域見解

北美憑藉其強大的轉化研究基礎設施、完善的臨床試驗網路、活躍的移植登記系統、先進的生物程序能力以及來自美國食品藥品監督管理局（FDA）和加拿大衛生署的法律規範，仍然是幹細胞研究的領先中心。美國在臨床研究密度、生產能力和受監管細胞療法的商業化方面處於主導地位，而加拿大則在再生醫學網路、公私合作研究計畫、臨床試驗協調和生物程序專業知識方面表現出色。

針對特定族群的幹細胞市場成長洞察

東協正崛起為具有成本競爭力的臨床研究和醫療服務中心。新加坡擁有完善的管理體制、生物醫學基礎設施和深厚的轉化研究實力，而泰國、馬來西亞、印尼、越南和菲律賓正在發展其醫療保健體系，並對再生醫學表現出日益濃厚的興趣。海灣合作理事會（GCC）成員國正利用其國家多元化策略，拓展生物技術、專科醫療、臨床研究和醫療旅遊，從而創造了對受監管的幹細胞服務以及與知名國際機構夥伴關係的需求。

主要國家幹細胞領域的發展趨勢

美國擁有全球最商業性環境，這得益於FDA監管的細胞療法、NIH資助的研究、頂尖的大學醫院、移植技術以及大規模的生物製藥生態系統。加拿大在再生醫學合作、臨床試驗技術和支持性研究網路方面具有優勢。墨西哥則透過利用私立醫療保健、專科醫院以及接近性北美臨床和生產網路的優勢，正在擴大市場需求。巴西在拉丁美洲處於領先地位，這得益於其大型醫院、大學、細胞療法研究計畫以及龐大的國內患者群體。

為幹細胞領域領導者提供的實用建議

產業領導者應從研發早期階段就優先考慮證據品質、生產可重複性和法規合規性。在擴大臨床活動規模之前，計畫應檢驗關鍵品質屬性、已驗證的療效檢測方法、細胞鑑定標記、無菌控制、捐贈者合格審查程序、身分控制、儲存歷史記錄以及長期追蹤計畫。儘早與監管機構合作可以減少延誤，並明確關於等效性、出貨檢測、安全性監測和治療後監測等方面的預期。

調查方法

本執行摘要基於三角驗證的二手檢驗和生命科學市場情報分析方法。資訊來源包括監管資料庫、來自美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、日本衛生署和世界衛生組織 (WHO) 的資源、ClinicalTrials.gov、WHO 國際臨床試驗註冊平台、國家臨床試驗註冊機構，以及來自移植和再生醫學組織（例如 CIBMTR、EBMT 和 ISSCR）

結論

幹細胞領域正步入一個更規範化的階段，臨床證據、生產控制、監管合規和負責任的商業化是穩健成長的關鍵。雖然成熟的移植應用提供了檢驗的基礎，但誘導多能幹細胞平台、類器官、基因修飾細胞、外泌體研究以及人工智慧驅動的分析技術正在拓展治療開發和藥物發現的長期機會。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章：幹細胞市場：依細胞類型分類

  • 成體幹細胞
  • 人類胚胎幹細胞
  • 誘導性多功能幹細胞

第8章 幹細胞市場：依細胞來源分類

  • 同種
  • 本土種植

第9章 幹細胞市場：依技術分類

  • 生物列印
  • 細胞培養
  • 基因編輯
    • CRISPR
    • 轉錄活化因子樣效應核酸酶

第10章 幹細胞市場：依細胞來源分類

  • 脂肪組織
  • 羊水來源細胞
  • 骨髓
  • 周邊血
  • 臍帶

第11章 幹細胞市場：依應用領域分類

  • 細胞庫
  • 藥物發現與測試
    • 藥物篩檢
    • 毒性測試
  • 再生醫學
    • 心血管系統
    • 神經病學
    • 整形外科
  • 研究與開發

第12章 幹細胞市場：依最終用戶分類

  • 生物製藥公司
  • 受託研究機構
  • 醫院和診所
  • 研究機構

第13章 幹細胞市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 幹細胞市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 幹細胞市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Advanced Cell Technology, Inc.
  • AlloSource, Inc.
  • Anterogen Co., Ltd.
  • Athersys Inc.
  • Becton, Dickinson and Company
  • Bioheart Inc.
  • Biorestorative Therapies Inc.
  • BrainStorm Cell Therapeutics Inc.
  • Bristol-Myers Squibb Company
  • Cellartis AB
  • Cellular Engineering Technologies Inc.
  • Charles River Laboratories International, Inc.
  • Danaher Corporation
  • Gamida Cell Ltd
  • GE HealthCare by General Electric Company
  • GenScript Biotech Corporation
  • Gilead Sciences, Inc.
  • HOLOSTEM Srl by Chiesi Farmaceutici SpA
  • JCR Pharmaceuticals Co., Ltd.
  • Lonza Group AG
  • Merck KGaA
  • Novartis AG
  • Pluristyx, Inc.
  • Sartorius AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-434CCDA04CF2

The Stem Cells Market is projected to grow by USD 33.18 billion at a CAGR of 11.26% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 15.72 billion
Estimated Year [2026] USD 17.40 billion
Forecast Year [2032] USD 33.18 billion
CAGR (%) 11.26%

Stem Cells Executive Summary

Stem cells sit at the center of regenerative medicine, cell therapy, disease modeling, drug discovery, and biomanufacturing. The field spans hematopoietic stem cells used in transplantation, mesenchymal stromal cells studied for immunomodulation and tissue repair, embryonic stem cells, induced pluripotent stem cells, and adult tissue-specific stem cells. Commercial momentum is being shaped by the convergence of clinical demand for durable therapies, better characterization tools, scalable manufacturing, and clearer regulatory expectations from agencies such as the U.S. FDA, EMA, PMDA, Health Canada, and Japan's MHLW.

The strongest near-term demand is anchored in validated clinical use cases, especially hematopoietic stem cell transplantation and approved cord-blood-derived hematopoietic progenitor cell products. Long-term growth is tied to iPSC-derived cell therapies, organoids, exosome research, stem-cell-enabled drug screening, and advanced cell-based disease models. For decision-makers, the market opportunity is less about a single technology and more about building compliant, reproducible, and evidence-generating platforms that can move from laboratory innovation to regulated clinical and commercial deployment.

Transformative Shifts in the Stem Cells Landscape

The stem cells landscape is moving from exploratory research toward platform-based clinical translation. A decade ago, many programs were limited by inconsistent cell characterization, small-batch production, and uncertain clinical endpoints. Today, single-cell analysis, potency assays, closed-system processing, cryopreservation improvements, digital batch records, and standardized donor-screening practices are helping developers reduce variability and improve comparability across clinical phases.

Transformative shifts are also occurring in disease focus and operating models. Oncology, hematology, musculoskeletal disorders, autoimmune diseases, ophthalmology, diabetes, and neurodegenerative conditions remain high-priority areas, while drug developers increasingly use stem-cell-derived models to de-risk pipelines before human trials. Strategic partnerships among biopharma developers, academic medical centers, contract development and manufacturing organizations, transplant networks, and cord blood banks are becoming central to scaling therapies while meeting good manufacturing practice, pharmacovigilance, and long-term follow-up requirements.

Cumulative Impact of Artificial Intelligence on Stem Cells

Artificial intelligence is becoming a practical accelerator across stem cell research and commercialization. In discovery, machine learning supports single-cell transcriptomics interpretation, cell-state classification, differentiation protocol optimization, image-based phenotyping, and target identification. In manufacturing, computer vision and predictive analytics can monitor morphology, culture conditions, contamination risk, media performance, and batch consistency, reducing reliance on subjective manual assessment.

The cumulative impact of AI is most visible where large biological datasets intersect with repeatable process controls. AI-enabled quality analytics can help predict potency, flag deviations earlier, and shorten development cycles when supported by validated datasets and regulatory-grade documentation. However, industry leaders must address data provenance, model explainability, bias in training datasets, cybersecurity, and compliance with evolving rules for software, laboratory automation, and clinical decision support. AI will not replace biological validation, but it can materially improve the speed, traceability, and reproducibility of stem cell innovation.

Key Regional Insights Across the Stem Cells Landscape

North America remains a leading stem cells hub because of deep translational research infrastructure, established clinical trial networks, active transplant registries, sophisticated bioprocessing capacity, and regulatory oversight by the FDA and Health Canada. The United States leads in clinical research density, manufacturing capability, and regulated cell therapy commercialization, while Canada contributes strength in regenerative medicine networks, public-private research programs, clinical trial coordination, and bioprocessing expertise.

Europe benefits from advanced therapy medicinal product regulation, strong academic hospitals, national health systems, and coordinated research funding across the European Union, with Germany, France, Spain, Italy, and the United Kingdom supporting robust clinical and manufacturing ecosystems. Asia-Pacific is a fast-moving innovation arena, led by Japan's regenerative medicine framework and iPSC leadership, China's expanding clinical trial base and manufacturing scale, South Korea's advanced cell therapy ecosystem, Australia's high-quality trial infrastructure, and India's growing biomanufacturing and clinical research base.

Latin America is advancing through Brazil and Mexico, where clinical research capacity, public health demand, university hospitals, and private hospital networks support selective growth in regulated stem cell applications. The Middle East, particularly GCC countries, is investing in medical tourism, specialty hospitals, biotechnology diversification, and internationally aligned healthcare infrastructure. Africa remains earlier-stage but strategically important, with opportunities in cord blood banking, academic collaborations, transplant capacity-building, and ethical frameworks for regulated regenerative medicine.

Key Group Insights for Stem Cells Growth

ASEAN is emerging as a cost-competitive clinical research and medical services corridor, with Singapore providing regulatory sophistication, biomedical infrastructure, and translational research depth while Thailand, Malaysia, Indonesia, Vietnam, and the Philippines develop healthcare capacity and regenerative medicine interest. The GCC is using national diversification strategies to expand biotechnology, specialty care, clinical research, and medical tourism, creating demand for compliant stem cell services and partnerships with established global institutions.

The European Union remains pivotal through harmonized advanced therapy regulation, Horizon Europe research funding, shared scientific standards, and cross-border clinical research networks. BRICS countries provide scale, patient diversity, manufacturing potential, and rising public investment in biotechnology, although regulatory maturity and reimbursement pathways vary considerably across members. G7 markets continue to set benchmarks for evidence generation, reimbursement scrutiny, intellectual property protection, GMP manufacturing, and post-approval surveillance. NATO members are not a healthcare market bloc, but their overlapping strengths in biomedical research, supply-chain resilience, biosecurity, and defense-linked health preparedness influence strategic investment in advanced therapies and regenerative medicine infrastructure.

Key Country Insights in Stem Cells

The United States is the most commercially mature stem cells environment, driven by FDA-regulated cell therapies, NIH-funded research, leading academic medical centers, transplant expertise, and a large biopharma ecosystem. Canada has strong regenerative medicine coordination, clinical trial expertise, and supportive research networks, while Mexico is building demand through private healthcare, specialist hospitals, and proximity to North American clinical and manufacturing networks. Brazil leads Latin America with major hospitals, universities, cell therapy research programs, and a large domestic patient base.

In Europe, the United Kingdom combines cell and gene therapy infrastructure with strong translational science and clinical trial capabilities, Germany leads in biomanufacturing and hospital-based research, France supports national innovation programs and academic medicine, Italy and Spain contribute active transplant and regenerative medicine networks, and Russia maintains scientific capacity despite market-access and geopolitical constraints. In Asia-Pacific, China is scaling clinical research and manufacturing, India is expanding biotechnology capacity and clinical trial infrastructure, Japan benefits from a defined regenerative medicine pathway and iPSC leadership, Australia offers high-quality early-phase trials and strong regulatory standards, and South Korea has a developed cell therapy industry, advanced hospital system, and supportive innovation policies.

Actionable Recommendations for Stem Cells Leaders

Industry leaders should prioritize evidence quality, manufacturing reproducibility, and regulatory alignment from the earliest stages of development. Programs should define critical quality attributes, validated potency assays, cell identity markers, sterility controls, donor eligibility procedures, chain-of-identity controls, chain-of-custody documentation, and long-term follow-up plans before scaling clinical activity. Early engagement with regulators can reduce delays and clarify expectations for comparability, release testing, safety monitoring, and post-treatment surveillance.

Organizations should invest in closed and automated manufacturing, digital quality systems, cryogenic logistics, validated analytics, and AI-supported process monitoring. Partnerships with academic centers, CDMOs, cord blood banks, transplant groups, and hospital networks can accelerate recruitment and operational execution. Commercial planning should include payer evidence, health economics, real-world data capture, patient access design, and ethical communication that avoids overstating unapproved stem cell interventions. The most defensible strategies will combine scientific rigor with scalable operations and transparent patient safety practices.

Research Methodology

This executive summary is built on triangulated secondary research and life sciences market intelligence practices. Inputs include regulatory databases and guidance from the FDA, EMA, PMDA, Health Canada, WHO resources, ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform, national trial registries, and public information from transplant and regenerative medicine organizations such as CIBMTR, EBMT, ISSCR, and recognized cord blood and cell therapy bodies.

The assessment also reviews peer-reviewed literature, patent activity, public disclosures, investor presentations, reimbursement and policy updates, hospital and academic program information, and manufacturing capacity signals. Insights are validated through cross-comparison of regulatory status, clinical evidence, regional infrastructure, and commercialization readiness. No section relies on promotional claims from unverified clinics, and conclusions emphasize regulated, evidence-backed stem cell applications.

Conclusion

The stem cells landscape is entering a more disciplined phase in which credible growth depends on clinical evidence, manufacturing control, regulatory compliance, and responsible commercialization. Established transplantation uses provide a validated foundation, while iPSC platforms, organoids, engineered cells, exosome research, and AI-enabled analytics expand the long-term opportunity across therapy development and drug discovery.

Regional competition is intensifying as North America and Europe deepen clinical translation, Asia-Pacific scales innovation, and emerging regions invest in capacity. The winners will be organizations that convert biological complexity into repeatable products, generate durable safety and efficacy data, and build trusted ecosystems with regulators, clinicians, manufacturers, and patients. Stem cells remain one of the most important frontiers in regenerative medicine, but sustainable leadership will come from evidence, reproducibility, and patient safety rather than hype.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Stem Cells Market, by Cell Type

  • 7.1. Adult Stem Cells
  • 7.2. Human Embryonic Stem Cells
  • 7.3. Induced Pluripotent Stem Cells

8. Stem Cells Market, by Cell Source

  • 8.1. Allogeneic
  • 8.2. Autologous

9. Stem Cells Market, by Technology

  • 9.1. Bioprinting
  • 9.2. Cell Culture
  • 9.3. Gene Editing
    • 9.3.1. CRISPR
    • 9.3.2. Transcription Activator-Like Effector Nuclease

10. Stem Cells Market, by Cell Source

  • 10.1. Adipose Tissue
  • 10.2. Amniotic Cells
  • 10.3. Bone Marrow
  • 10.4. Peripheral Blood
  • 10.5. Umbilical Cord

11. Stem Cells Market, by Application

  • 11.1. Cell Banking
  • 11.2. Drug Discovery & Testing
    • 11.2.1. Pharmaceutical Screening
    • 11.2.2. Toxicity Testing
  • 11.3. Regenerative Medicine
    • 11.3.1. Cardiovascular
    • 11.3.2. Neurology
    • 11.3.3. Orthopaedics
  • 11.4. Research & Development

12. Stem Cells Market, by End User

  • 12.1. Biopharmaceutical Companies
  • 12.2. Contract Research Organizations
  • 12.3. Hospitals & Clinics
  • 12.4. Research Institutes

13. Stem Cells Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Stem Cells Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Stem Cells Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Advanced Cell Technology, Inc.
  • 17.2. AlloSource, Inc.
  • 17.3. Anterogen Co., Ltd.
  • 17.4. Athersys Inc.
  • 17.5. Becton, Dickinson and Company
  • 17.6. Bioheart Inc.
  • 17.7. Biorestorative Therapies Inc.
  • 17.8. BrainStorm Cell Therapeutics Inc.
  • 17.9. Bristol-Myers Squibb Company
  • 17.10. Cellartis AB
  • 17.11. Cellular Engineering Technologies Inc.
  • 17.12. Charles River Laboratories International, Inc.
  • 17.13. Danaher Corporation
  • 17.14. Gamida Cell Ltd
  • 17.15. GE HealthCare by General Electric Company
  • 17.16. GenScript Biotech Corporation
  • 17.17. Gilead Sciences, Inc.
  • 17.18. HOLOSTEM S.r.l. by Chiesi Farmaceutici S.p.A
  • 17.19. JCR Pharmaceuticals Co., Ltd.
  • 17.20. Lonza Group AG
  • 17.21. Merck KGaA
  • 17.22. Novartis AG
  • 17.23. Pluristyx, Inc.
  • 17.24. Sartorius AG
  • 17.25. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL STEM CELLS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL STEM CELLS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL STEM CELLS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL STEM CELLS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL STEM CELLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL STEM CELLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ADULT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ADULT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ADULT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HUMAN EMBRYONIC STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL INDUCED PLURIPOTENT STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOPRINTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOPRINTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOPRINTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL GENE EDITING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL GENE EDITING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL GENE EDITING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CRISPR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CRISPR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CRISPR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR NUCLEASE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ADIPOSE TISSUE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AMNIOTIC CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AMNIOTIC CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AMNIOTIC CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BONE MARROW MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BONE MARROW MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BONE MARROW MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PERIPHERAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL UMBILICAL CORD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL UMBILICAL CORD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL UMBILICAL CORD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL CELL BANKING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL BANKING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL CELL BANKING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG DISCOVERY & TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG DISCOVERY & TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG DISCOVERY & TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PHARMACEUTICAL SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PHARMACEUTICAL SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PHARMACEUTICAL SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOXICITY TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TOXICITY TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TOXICITY TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL REGENERATIVE MEDICINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL CARDIOVASCULAR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL CARDIOVASCULAR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL CARDIOVASCULAR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL NEUROLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL NEUROLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ORTHOPAEDICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ORTHOPAEDICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ORTHOPAEDICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL RESEARCH & DEVELOPMENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BIOPHARMACEUTICAL COMPANIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL CONTRACT RESEARCH ORGANIZATIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL STEM CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. MIDDLE EAST STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. AFRICA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 144. AFRICA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 146. AFRICA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL STEM CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 154. ASEAN STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 155. ASEAN STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. ASEAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 157. ASEAN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 158. ASEAN STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 159. ASEAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 160. ASEAN STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 161. ASEAN STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 162. ASEAN STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 163. ASEAN STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. GCC STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. GCC STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. GCC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 167. GCC STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. GCC STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 169. GCC STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 170. GCC STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. GCC STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 172. GCC STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 173. GCC STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. BRICS STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 185. BRICS STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. BRICS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 187. BRICS STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. BRICS STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 189. BRICS STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 190. BRICS STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. BRICS STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 192. BRICS STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 193. BRICS STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. G7 STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. G7 STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. G7 STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 197. G7 STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 198. G7 STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 199. G7 STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 200. G7 STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. G7 STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 202. G7 STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 203. G7 STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. NATO STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 205. NATO STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. NATO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 207. NATO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. NATO STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 209. NATO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 210. NATO STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. NATO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 212. NATO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 213. NATO STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. GLOBAL STEM CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. CANADA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. CANADA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 228. CANADA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 229. CANADA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 230. CANADA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 231. CANADA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 232. CANADA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 233. CANADA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 234. CANADA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. MEXICO STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. MEXICO STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 238. MEXICO STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 239. MEXICO STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 240. MEXICO STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 241. MEXICO STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 242. MEXICO STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 243. MEXICO STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 244. MEXICO STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. BRAZIL STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. BRAZIL STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 248. BRAZIL STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. BRAZIL STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 250. BRAZIL STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 251. BRAZIL STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 252. BRAZIL STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 253. BRAZIL STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 254. BRAZIL STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED KINGDOM STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. GERMANY STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 266. GERMANY STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 268. GERMANY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. GERMANY STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 270. GERMANY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 271. GERMANY STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 272. GERMANY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 273. GERMANY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 274. GERMANY STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. FRANCE STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. RUSSIA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 286. RUSSIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 288. RUSSIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 289. RUSSIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 290. RUSSIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 291. RUSSIA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 292. RUSSIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 293. RUSSIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 294. RUSSIA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. ITALY STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 304. ITALY STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. SPAIN STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 306. SPAIN STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 308. SPAIN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 309. SPAIN STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 310. SPAIN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 311. SPAIN STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. SPAIN STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 313. SPAIN STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 314. SPAIN STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. CHINA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. CHINA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. CHINA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 320. CHINA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 321. CHINA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 322. CHINA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 323. CHINA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 324. CHINA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 325. INDIA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 326. INDIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 327. INDIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 328. INDIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 329. INDIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 330. INDIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 331. INDIA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 332. INDIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 333. INDIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 334. INDIA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 335. JAPAN STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 336. JAPAN STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 337. JAPAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 338. JAPAN STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 339. JAPAN STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 340. JAPAN STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 341. JAPAN STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 342. JAPAN STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 343. JAPAN STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 344. JAPAN STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 345. AUSTRALIA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 346. AUSTRALIA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 347. AUSTRALIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 348. AUSTRALIA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 349. AUSTRALIA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 350. AUSTRALIA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 351. AUSTRALIA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 352. AUSTRALIA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 353. AUSTRALIA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 354. AUSTRALIA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 355. SOUTH KOREA STEM CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 356. SOUTH KOREA STEM CELLS MARKET SIZE, BY CELL TYPE, 2018-2032 (USD MILLION)
  • TABLE 357. SOUTH KOREA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 358. SOUTH KOREA STEM CELLS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 359. SOUTH KOREA STEM CELLS MARKET SIZE, BY GENE EDITING, 2018-2032 (USD MILLION)
  • TABLE 360. SOUTH KOREA STEM CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 361. SOUTH KOREA STEM CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 362. SOUTH KOREA STEM CELLS MARKET SIZE, BY DRUG DISCOVERY & TESTING, 2018-2032 (USD MILLION)
  • TABLE 363. SOUTH KOREA STEM CELLS MARKET SIZE, BY REGENERATIVE MEDICINE, 2018-2032 (USD MILLION)
  • TABLE 364. SOUTH KOREA STEM CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)